伊立替康联合放疗在小细胞肺癌脑转移患者一线治疗中的有效性和安全性

The Efficacy and Safety of Irinotecan Combined with Radiotherapy in the First-line Treatment of Patients with Brain Metastases from Small Cell Lung Cancer

目的:探讨伊立替康联合放疗在小细胞肺癌脑转移患者一线治疗中的有效性和安全性。方法:选择2013年1月-2015年12月本院小细胞肺癌脑转移患者100例,按照随机数字表法分为放疗组和联合组,各50例。放疗组单纯进行放疗治疗,联合组采用伊立替康联合放疗,比较两组患者治疗前后的卡氏评分、无疾生存时间、疾病治疗客观有效率、疾病控制率、不良反应发生率。结果:治疗前,两组患者的卡氏评分比较,差异无统计学意义(P>0.05);治疗后,联合组患者的卡氏评分优于放疗组,差异有统计学意义(P<0.05)。联合组无疾生存时间为(5.45±1.24)个月,明显长于放疗组的(4.21±1.16)个月,差异有统计学意义(P<0.05)。联合组疾病治疗客观有效率、疾病控制率分别为58.0%、40.0%,均显著高于放疗组的40.0%、30.0%,差异均有统计学意义(P<0.05)。两组的不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:伊立替康联合放疗在小细胞肺癌脑转移患者一线治疗中的有效性和安全性均较高,可有效提高疾病控制率,无严重毒副作用,患者可耐受,值得推广。

Objective：To investigate the efficacy and safety of Irinotecan combined with radiotherapy in the first-line treatment in patients with brain metastases from small cell lung cancer.Method：100 patients with brain metastases from small cell lung cancer in our hospital from January 2013 to December 2015,according to the random number table method,the patients were divided into radiotherapy group and combination group,50 cases in each group.Radiotherapy group was treated with radiotherapy alone,the combination group received Irinotecan combined with radiotherapy.Karnofsky score,no disease survival time,objective effective rate,disease control rate and incidence of adverse reactions of the two groups before and after treatment were compared.Result：Before treatment,there was no significant difference in the Karnofsky score of the two groups（P〈0.05）,After treatment,the Karnofsky score of the combination group was better than that in radiotherapy group,the difference was statistically significant（P〈0.05）.The no disease survival time of the combination group was（5.45±1.24）months,significantly longer than（4.21±1.16） months of the radiotherapy group,the difference was statistically significant（P〈0.05）.The objective effective rate and disease control rate of the combination group were 58.0% and 40.0%,significantly higher than 40.0% and 30.0% of the radiotherapy group,the differences were statistically significant（P〈0.05）.Comparison of adverse reactions between the two groups,the differences were no statistically significant（P〈0.05）.Conclusion：The efficacy and safety of Irinotecan combined with radiotherapy in the first-time treatment of patients with brain metastases from small cell lung cancer are all high,can effectively improve the disease control rate,no serious side effects,patients can be tolerated,worthy of promotion.